The primary endpoints for efficacy are target protein expression levels in the desired tissue, typically quantified via ELISA, Western Blot, or reporter gene activity (e.g., Luciferase). Secondary endpoints include the duration of protein expression and functional assays relevant to the therapeutic hypothesis.

We assess immunogenicity by profiling cytokine release (e.g., IL-6, TNF-α) at early time points post-administration and by measuring anti-PEG antibody responses for PEGylated lipids. Comparing these responses directly between formulations provides a clear index of their relative immunogenic potential.

Benchmarking against a known standard, such as a formulation with components used in an approved therapeutic, provides the necessary context for your data. It establishes a performance baseline and allows for a direct, quantitative assessment of improvement in delivery efficiency, expression, or safety profile, which is a key component of an IND data package.

The primary drivers are the physicochemical properties of the LNP, including particle size, surface charge, and the pKa of the ionizable lipid. These factors dictate interactions with serum proteins and subsequent uptake by tissues, particularly the liver and spleen. A comprehensive study will map biodistribution to these core LNP characteristics.